質量光測定による抗体-抗原アフィニティーの迅速な測定

Executive Industry Relevance

Rapid, label-free quantification of antibody-antigen affinity is essential for accelerating therapeutic antibody discovery and optimizing candidate selection. Mass photometry enables single-molecule resolution of binding events, supporting predictive confidence in early-stage target validation and mechanistic de-risking. This approach streamlines portfolio triage by delivering quantitative affinity and stoichiometry data with minimal sample requirements.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables direct measurement of antibody-antigen binding affinities without labeling artifacts.
• Provides quantitative stoichiometry and oligomeric state data for mechanistic de-risking.
• Supports rapid hypothesis testing and functional target validation with picomole-scale samples.
• Facilitates portfolio triage by distinguishing high-affinity candidates early.

Screening & Assay Development

• Delivers validated, quantitative affinity data for downstream screening workflows.
• Standardizes assay outputs by eliminating immobilization and label variability.
• Enables reproducible, scalable affinity measurements across antibody panels.
• Supports reliable compound evaluation by confirming binding specificity and purity.

Translational & Preclinical Research

• Aligns affinity measurements with translational biomarker requirements when antigens are disease-relevant.
• Ensures continuity from discovery to preclinical validation by providing robust KD values.
• Reduces risk of late-stage attrition due to inaccurate binding characterization.

Pipeline & Workflow Integration

Mass photometry positions affinity determination at the interface of early discovery and lead identification, enabling rapid go/no-go decisions before resource-intensive preclinical work.

• Discovery Biology: Supports hypothesis testing and pathway clarification by quantifying binding events at single-molecule resolution.
• Screening: Provides reproducible, quantitative affinity outputs for assay readiness and compound triage.
• Analytics: Delivers molecular mass distributions, stoichiometry, and KD values for comparative analysis.
• Translational Research: Facilitates alignment with disease-relevant targets when sample purity and size criteria are met.
• Enterprise Reuse: Offers a reusable, label-free platform for diverse protein-protein interaction studies above 50 kDa.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
• Operational Value: Streamlines workflows with rapid, standardized, and scalable affinity measurements.
• Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio advancement.
• Portfolio Impact: Supports risk-adjusted prioritization by providing robust, quantitative binding data early in the pipeline.

Implementation Considerations

• Requires expertise in single-molecule data analysis and quantitative fitting.
• Needs access to mass photometry instrumentation and compatible analytical software.
• Demands cross-team standardization of sample preparation and data interpretation.
• Best suited for proteins above 50 kDa and sub-micromolar affinities with high sample purity.
• Limited by reduced sensitivity for small antigens or low-affinity interactions.

Biopharma FAQs